A Novel Therapeutic Gel Option for Improvement of Joint Function in OsteoArthritic Patients

Osteoarthritis [OA] is a significant global healthcare challenge. It is a long-term chronic disease, is characterized by the thinning of synovial fluid and subsequent deterioration of cartilage in joints which results in bones rubbing together and creating stiffness, immobilising pain, and impaired movement. OA most commonly affects seniors and is expected to sharply increase with an aging population. This project seeks to full study the Feasibility of employing a novel therapeutic gel for the improvement of joint function in osteoarthritic patients. It will investigate translating the use of a patented microgel targeted for use in the spine, and assess the idea of leveraging the physical capacities of this 'SXM' gel to create intra-articular cushioning. The gel would be introduced to the joint through a small needle without creating further damage. As the gel cures it becomes heavily viscous and can act as a cushion gently distributing the load over a larger surface thus minimising the risk or the speed of further damages allowing natural motion with reduced pain. Gelexir Healthcare Ltd who have developed the SXM gel will simultaneously develop a full commercialisation Business Plan containing full market details, commercial strategy and estimates the economic benefits to patients and healthcare providers.